Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2019

View Archived Issues

Failure of AMPK caused by multiple uremic factors is a key mechanism of energy depletion in CKD

Localized cell death processes contribute to neurodegeneration

Epigenetic protein switches function after development

New HPV vaccine overcomes viral-type specificity

PIN Pharma presents first-in-human study results for its precision immune stimulant PIN-2

Medivir patents new MALT1 inhibitors

Preliminary data announced from phase I study of HPN-424 in patients with prostate cancer

Eloxx Pharmaceuticals synthesizes compounds for genetic disorders

Results presented from phase III CASSINI study evaluating rivaroxaban thromboprophylaxis

Institute of Materia Medica of Beijing presents compounds for cough

Deciphera Pharmaceuticals reports preliminary data from its ongoing phase I study of DCC-3014

Merck & Co. discloses muscarinic M4 receptor PAMs

Boehringer Ingelheim patents VNN1 inhibitors

FDA approves Sprycel with chemotherapy for pediatric Ph+ ALL

Propanc Biopharma enters collaboration with University of Jaen

Phase II trial of AEVI-001 in pediatric ADHD does not meet primary endpoint

Adlai and Merck & Co. enter clinical trial collaboration to study AN-0025 with Keytruda

Chinese NMPA accepts IND for Asceltis Pharma's third HCV drug ASC-21

Flexion initiates phase III study of Zilretta for hip osteoarthritis

TIM-3/Gal-9 autocrine signaling loop unveiled as therapeutic target for AML

FDA accepts IND for phase Ib study of DM-199 for diabetes-related CKD

U.S. patients to join global phase II trial of mavrilimumab for giant cell arteritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...